Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 1426 for:    survival | Neuroendocrine Tumors

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET) (SEQTOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02246127
Recruitment Status : Active, not recruiting
First Posted : September 22, 2014
Last Update Posted : March 5, 2020
Sponsor:
Collaborators:
European Neuroendocrine Tumor Society
Kantar Health
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : December 2019
Estimated Study Completion Date : July 2021